Teladoc Health, Inc. (NYSE:TDOC) Receives Average Rating of "Hold" from Analysts

Shares of Teladoc Health, Inc. (NYSE:TDOC - Get Free Report) have received a consensus rating of "Hold" from the twenty research firms that are covering the stock, Marketbeat.com reports. Fourteen research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $11.97.

TDOC has been the subject of a number of research reports. DA Davidson lowered their target price on Teladoc Health from $12.00 to $8.00 and set a "neutral" rating for the company in a report on Thursday, August 1st. Piper Sandler reduced their price target on Teladoc Health from $25.00 to $10.00 and set an "overweight" rating for the company in a research report on Tuesday, August 6th. TD Cowen lowered their price objective on shares of Teladoc Health from $9.00 to $8.00 and set a "hold" rating on the stock in a report on Thursday, October 31st. Needham & Company LLC reaffirmed a "hold" rating on shares of Teladoc Health in a research report on Thursday, August 1st. Finally, Barclays boosted their price target on shares of Teladoc Health from $10.00 to $12.00 and gave the stock an "overweight" rating in a research report on Thursday, October 31st.

Teladoc Health Trading Down 2.3 %

TDOC stock traded down $0.22 during midday trading on Wednesday, hitting $9.48. 4,119,410 shares of the company's stock were exchanged, compared to its average volume of 5,506,972. Teladoc Health has a one year low of $6.76 and a one year high of $22.54. The stock's fifty day moving average price is $8.79 and its 200-day moving average price is $9.44. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.69 and a current ratio of 1.73.

Teladoc Health (NYSE:TDOC - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The health services provider reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.10. The business had revenue of $640.51 million during the quarter, compared to analyst estimates of $630.50 million. Teladoc Health had a negative return on equity of 10.06% and a negative net margin of 37.91%. Research analysts forecast that Teladoc Health will post -1.19 earnings per share for the current fiscal year.

Insider Buying and Selling at Teladoc Health

In related news, Director Thomas Mckinley bought 4,000 shares of Teladoc Health stock in a transaction that occurred on Thursday, September 12th. The stock was acquired at an average price of $7.69 per share, with a total value of $30,760.00. Following the acquisition, the director now owns 39,077 shares of the company's stock, valued at approximately $300,502.13. This represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CFO Mala Murthy sold 8,750 shares of the business's stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.16, for a total value of $62,650.00. Following the completion of the sale, the chief financial officer now owns 85,767 shares of the company's stock, valued at approximately $614,091.72. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Thomas Mckinley purchased 4,000 shares of the firm's stock in a transaction that occurred on Thursday, September 12th. The stock was acquired at an average price of $7.69 per share, for a total transaction of $30,760.00. Following the completion of the purchase, the director now directly owns 39,077 shares of the company's stock, valued at $300,502.13. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 20,051 shares of company stock worth $143,565 over the last ninety days. Insiders own 0.95% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Massachusetts Financial Services Co. MA boosted its stake in shares of Teladoc Health by 477.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 370,093 shares of the health services provider's stock valued at $3,397,000 after buying an additional 305,961 shares during the period. Intech Investment Management LLC acquired a new position in Teladoc Health in the 3rd quarter valued at $310,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Teladoc Health by 15.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,701,161 shares of the health services provider's stock valued at $15,617,000 after acquiring an additional 228,004 shares during the period. Jennison Associates LLC acquired a new stake in shares of Teladoc Health during the 3rd quarter worth $1,544,000. Finally, Royce & Associates LP bought a new position in shares of Teladoc Health in the third quarter worth $167,000. Institutional investors and hedge funds own 76.82% of the company's stock.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.